Home > Insider Trading > Filing (0001140361-11-011228)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1389046	F James Polewaczyk	One Idexx Drive Westbrook ME 04092	Corporate Vice President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-02-17	5,265	$56.95	8,272	No	4	M	Direct
Common Stock	Acquisiton	2011-02-17	8,000	$34.37	16,272	No	4	M	Direct
Common Stock	Acquisiton	2011-02-17	2,000	$53.31	18,272	No	4	M	Direct
Common Stock	Acquisiton	2011-02-17	3,603	$56.95	21,875	No	4	M	Direct
Common Stock	Disposition	2011-02-17	12,000	$77.58	9,875	No	4	S	Direct
Common Stock	Disposition	2011-02-17	5,236	$77.66	4,639	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Incentive Stock Option (right to buy)	Disposition	2011-02-17	5,265	$0.00	5,265	$56.95
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2011-02-17	8,000	$0.00	8,000	$34.37
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2011-02-17	2,000	$0.00	2,000	$53.31
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2011-02-17	3,603	$0.00	3,603	$56.95

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,510	2015-02-13	No	4	M	Direct
9,837	2016-02-13	No	4	M	Direct
9,657	2017-02-13	No	4	M	Direct
2,401	2015-02-13	No	4	M	Direct

Footnotes

The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $77.50 to $77.72, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $77.63 to $77.695, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/14/2009) of the date of grant.
Grant of options to buy shares of common stock becomes exercisable as to 4,149 shares on 02/14/2010, 02/14/2011, 02/14/2012, 02/14/2013, and the remaining 1,241 shares on 02/14/2014.
Grant of options to buy shares of common stock becomes exercisable as to 2,707 shares on 02/14/2011 and 02/14/2012, 2,706 shares on 02/14/2013 and 02/14/2014, and the remaining 831 shares on 02/14/2015.
Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/14/2009) of the date of grant.